“…Treatment with somatostatin or octreotide has been implemented in more than half of the patients from the reviewed literature, in addition to dietary modifications (56,3%) and it achieved a desired therapeutic effect in 63.2 % of them. [2-3], [11][12], [17], [19][20], [25]- [28], [31]- [33], [37], [39], [41]- [43], [45], [52], [54]-[57], [62]- [64], [66], [70][71], [73], [77]- [80], [84], [86][87], [91][92], [95][96], [98], [103] Due to certain differences in pharmacokinetic properties and route of administration, octreotide is a more popular choice (79,9 % of patients) than somatostatin (10,4 %) [3], [11][12], [17], [19][20], [25]- [27], [31][32][33], [37], [39], [41]- [43], [45], [52],...…”